KR20150034170A - 온도 안정성 백신 제형 - Google Patents

온도 안정성 백신 제형 Download PDF

Info

Publication number
KR20150034170A
KR20150034170A KR20157000755A KR20157000755A KR20150034170A KR 20150034170 A KR20150034170 A KR 20150034170A KR 20157000755 A KR20157000755 A KR 20157000755A KR 20157000755 A KR20157000755 A KR 20157000755A KR 20150034170 A KR20150034170 A KR 20150034170A
Authority
KR
South Korea
Prior art keywords
composition
vaccine
rpa
sugar
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20157000755A
Other languages
English (en)
Korean (ko)
Inventor
지 룩
크리스챤 페르난도 루이즈
아론 폴 마일즈
리차드 윌리엄 웰치
Original Assignee
이머전트 프로덕트 디벨롭먼트 게이더스버그 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이머전트 프로덕트 디벨롭먼트 게이더스버그 인코포레이티드 filed Critical 이머전트 프로덕트 디벨롭먼트 게이더스버그 인코포레이티드
Publication of KR20150034170A publication Critical patent/KR20150034170A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/07Bacillus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR20157000755A 2012-06-25 2013-06-25 온도 안정성 백신 제형 Withdrawn KR20150034170A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664062P 2012-06-25 2012-06-25
US61/664,062 2012-06-25
US201361801385P 2013-03-15 2013-03-15
US61/801,385 2013-03-15
PCT/US2013/047712 WO2014004578A1 (en) 2012-06-25 2013-06-25 Temperature stable vaccine formulations

Publications (1)

Publication Number Publication Date
KR20150034170A true KR20150034170A (ko) 2015-04-02

Family

ID=49783811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157000755A Withdrawn KR20150034170A (ko) 2012-06-25 2013-06-25 온도 안정성 백신 제형

Country Status (13)

Country Link
US (1) US20150335752A1 (enExample)
EP (1) EP2863898A4 (enExample)
JP (1) JP2015525748A (enExample)
KR (1) KR20150034170A (enExample)
CN (1) CN104470506A (enExample)
AU (1) AU2013280480B2 (enExample)
CA (1) CA2877130A1 (enExample)
HK (1) HK1207312A1 (enExample)
IL (1) IL236380A0 (enExample)
IN (1) IN2015MN00038A (enExample)
RU (1) RU2014151424A (enExample)
SG (1) SG11201408262XA (enExample)
WO (1) WO2014004578A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100344A1 (en) * 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
US20170007690A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilization of anthrax recombinant protective antigen
WO2017007835A1 (en) 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for nanoemulsion vaccine formulations
EP3319930A4 (en) * 2015-07-07 2019-04-10 NanoBio Corporation METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS
US11510871B2 (en) 2016-09-16 2022-11-29 Leukocare Ag Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US20190216925A1 (en) * 2016-09-16 2019-07-18 Leukocare Ag A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing
EP3512939A1 (en) 2016-09-16 2019-07-24 Leukocare AG A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1188171C (zh) * 1994-06-02 2005-02-09 廓德伦特控股剑桥有限公司 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物
US7201912B2 (en) * 2002-04-12 2007-04-10 Emergent Biodefense Operation Lansing Inc. Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CN100556400C (zh) * 2006-07-20 2009-11-04 上海交通大学 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法
WO2008079464A2 (en) * 2006-09-08 2008-07-03 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
US20110212127A1 (en) * 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
JP2012515752A (ja) * 2009-01-22 2012-07-12 ファーマシーネ,インコーポレイテッド 安定なワクチン組成物とその使用方法

Also Published As

Publication number Publication date
EP2863898A1 (en) 2015-04-29
WO2014004578A1 (en) 2014-01-03
RU2014151424A (ru) 2016-08-20
CA2877130A1 (en) 2014-01-03
CN104470506A (zh) 2015-03-25
US20150335752A1 (en) 2015-11-26
SG11201408262XA (en) 2015-01-29
IL236380A0 (en) 2015-02-26
AU2013280480B2 (en) 2018-03-15
EP2863898A4 (en) 2016-04-27
HK1207312A1 (en) 2016-01-29
AU2013280480A1 (en) 2015-01-22
JP2015525748A (ja) 2015-09-07
IN2015MN00038A (enExample) 2015-10-16

Similar Documents

Publication Publication Date Title
KR20150034170A (ko) 온도 안정성 백신 제형
JP5830009B2 (ja) Staphylococcusaureusに対して免疫化するための組成物
JP6435261B2 (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
US20150044251A1 (en) Stable compositions for immunising against staphylococcus aureus
US20230066762A1 (en) Immunogenic composition
Smallshaw et al. A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity
JP2015528457A (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
JP2018135388A (ja) シュードモナス抗原および抗原の組み合わせ
US10357559B2 (en) Temperature stable vaccine formulations
ES2346441T3 (es) Composiciones y procedimientos para activar una inmunidad innata y alergica.
CA2750321A1 (en) Stable vaccine compositions and methods of use
US10293041B2 (en) Multivalent stable vaccine composition and methods of making same
JP2015528456A (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
JP2015532594A (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
EP4058056A1 (en) Cholera vaccine formulation
WO2016007797A1 (en) Multivalent stable vaccine composition and methods of making same
NZ614460B2 (en) Vaccines and compositions against streptococcus pneumoniae

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid